View Important Safety Information

Contact a Representative About TECENTRIQ in Combination With COTELLIC^® (cobimetinib) and ZELBORAF^® (vemurafenib)

Please remember: this feature is intended for US healthcare professionals only.

Please complete the form below if you would like a Genentech representative to contact you regarding further information about TECENTRIQ (atezolizumab) in combination with COTELLIC (cobimetinib) and ZELBORAF (vemurafenib). You should receive a response within 2 business days.

Your contact information will only be used for a representative to respond to your information request. It will not be used for any other purpose unless you register for Genentech updates by checking the box below.

Personal information

*Indicates a required field.

First Name*

Last Name*

Email Address*

Confirm Email Address*

Zip Code of Practice Location*

Phone Number*

My request is regarding (check all that apply)

IMspire150 study information Managing patients on TECENTRIQ + COTELLIC + ZELBORAF Financial assistance programs Other questions about TECENTRIQ + COTELLIC + ZELBORAF

By submitting this form, you agree to allow Genentech and its agents to collect the information provided and to be contacted directly by a Genentech representative. Your information will not be used for any other purpose than for a representative to respond to your information request, or for us to send you other Genentech Oncology updates if you have registered to receive them.

Genentech will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Genentech and its agents. Genentech will only use your information in accordance with its Privacy Policy.

Thank you for contacting us about TECENTRIQ

Your request has been submitted.

One of our Genentech representatives will contact you directly within 2 business days.

Your contact information will not be used for any other purpose than for the representative to respond to your information request.

Indication

Unresectable or metastatic melanoma
TECENTRIQ, in combination with cobimetinib and vemurafenib, is indicated for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

Serious Adverse Reactions
Please refer to the full Prescribing Information for important dose management information specific to adverse reactions.

Immune-Mediated Pneumonitis

Immune-mediated pneumonitis or interstitial lung disease, including fatal cases, have occurred with TECENTRIQ treatment
In clinical studies of TECENTRIQ as a single agent, 2.5% of patients developed pneumonitis, including Grade 3 (0.6%), Grade 4 (0.1%), and Grade 5 (<0.1%) events
In a clinical study of TECENTRIQ in combination with cobimetinib and vemurafenib for melanoma, immune-mediated pneumonitis occurred in 13% of patients, including Grades 3 to 4 (1.3%) events
Monitor patients for signs and symptoms of pneumonitis. Evaluate patients with suspected pneumonitis with radiographic imaging. Administer corticosteroids followed by a taper. Withhold TECENTRIQ for Grade 2 and permanently discontinue for Grade 3 or 4 pneumonitis

Immune-Mediated Hepatitis

Liver test abnormalities and immune-mediated hepatitis, including fatal cases, have occurred with TECENTRIQ treatment
In clinical studies of TECENTRIQ as a single agent, hepatitis occurred in 9% of patients, including Grade 3 (2.3%), Grade 4 (0.6%), and Grade 5 (<0.1%) events
In a clinical study of TECENTRIQ in combination with cobimetinib and vemurafenib for melanoma, immune-mediated hepatitis occurred in 53% of patients, including Grades 3 to 4 (22%) and Grade 5 (<1%) events
Monitor patients for signs and symptoms of hepatitis, during and after discontinuation of TECENTRIQ, including clinical chemistry monitoring. Administer corticosteroids followed by a taper for immune-mediated hepatitis. Withhold TECENTRIQ for AST or ALT elevations more than 3 and up to 8 times the upper limit of normal or total bilirubin more than 1.5 and up to 3 times the upper limit of normal. Permanently discontinue TECENTRIQ for AST or ALT elevations more than 8 times the upper limit of normal or total bilirubin more than 3 times the upper limit of normal

Immune-Mediated Colitis

Immune-mediated diarrhea or colitis have occurred with TECENTRIQ treatment
In clinical studies of TECENTRIQ as a single agent, diarrhea or colitis occurred in 20% of patients, including Grade 3 (1.4%) events
In a clinical study of TECENTRIQ in combination with cobimetinib and vemurafenib for melanoma, diarrhea or colitis occurred in 50% of patients, including Grades 3 to 4 (3%) events
Monitor patients for signs and symptoms of diarrhea or colitis. Withhold TECENTRIQ for Grade 2 or 3 and permanently discontinue for Grade 4 diarrhea or colitis

Immune-Mediated Endocrinopathies

TECENTRIQ can cause immune-mediated endocrinopathies, including thyroid disorders; adrenal insufficiency; type 1 diabetes mellitus, including diabetic ketoacidosis; and hypophysitis/hypopituitarism
Withhold TECENTRIQ for Grades 2 to 4 endocrinopathies
Thyroid Disorders
- In clinical studies of TECENTRIQ as a single agent, hypothyroidism occurred in 4.6% of patients and hyperthyroidism occurred in 1.6% of patients
- In a clinical study of TECENTRIQ in combination with cobimetinib and vemurafenib for melanoma, hypothyroidism occurred in 26% of patients and hyperthyroidism occurred in 19% of patients, including Grades 3 to 4 (0.9%) events
- Monitor thyroid function prior to and during treatment with TECENTRIQ. Initiate hormone replacement therapy or medical management of hyperthyroidism as clinically indicated
Adrenal Insufficiency
- In clinical studies of TECENTRIQ as a single agent, adrenal insufficiency occurred in 0.4% of patients, including Grade 3 (<0.1%) events
- Monitor patients for clinical signs and symptoms of adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate corticosteroids and hormone replacement therapy as clinically indicated
Type 1 Diabetes Mellitus
- In clinical studies of TECENTRIQ as a single agent, type 1 diabetes mellitus occurred in <0.1% of patients
- Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated
Hypophysitis
- In clinical studies of TECENTRIQ as a single agent, Grade 2 hypophysitis occurred in <0.1% of patients
- For Grades 2 to 4 hypophysitis, initiate corticosteroids and hormone replacement therapy as clinically indicated

Other Immune-Mediated Adverse Reactions

TECENTRIQ can cause severe and fatal immune-mediated adverse reactions. These immune-mediated reactions may involve any organ system
In clinical studies of TECENTRIQ as a single agent or were reported in other products in this class, the immune-mediated adverse reactions occurring at an incidence of <1% were cardiac, dermatologic, gastrointestinal, general, hematological, musculoskeletal, neurological, ophthalmological, renal, and vascular
For suspected Grade 2 immune-mediated adverse reactions, exclude other causes and initiate corticosteroids as clinically indicated. For severe (Grade 3 or 4) adverse reactions, withhold TECENTRIQ and administer corticosteroids. Permanently discontinue TECENTRIQ for Grade 4 immune-mediated adverse reactions involving a major organ
Evaluate for Vogt-Koyanagi-Harada syndrome if uveitis occurs in combination with other immune-mediated adverse reactions

Infections

TECENTRIQ can cause severe infections including fatal cases
In clinical studies of TECENTRIQ as a single agent, infections occurred in 42% of patients, including Grade 3 (8.7%), Grade 4 (1.5%), and Grade 5 (1%) events
In a clinical study of TECENTRIQ in combination with cobimetinib and vemurafenib for melanoma, infections occurred in 60% of patients, including Grade 3 to 4 (9%) and Grade 5 (1.7%) events. The most common infection was upper respiratory tract infection
Monitor patients for signs and symptoms of infection. For Grade 3 or higher infections, withhold TECENTRIQ and resume once clinically stable

Infusion-Related Reactions

TECENTRIQ can cause severe or life-threatening infusion-related reactions
In clinical studies of TECENTRIQ as a single agent, infusion-related reactions occurred in 1.3% of patients, including Grade 3 (0.2%) events
Monitor patients for signs and symptoms of infusion-related reactions. Interrupt or slow the rate of infusion in patients with Grade 1 or 2 infusion-related reactions. Permanently discontinue TECENTRIQ in patients with Grade 3 or 4 infusion-related reactions

Embryo-Fetal Toxicity

Based on its mechanism of action, TECENTRIQ can cause fetal harm when administered to a pregnant woman. Verify pregnancy status of females of reproductive potential prior to initiating TECENTRIQ. Advise females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TECENTRIQ and for at least 5 months after the last dose

Nursing Mothers/Fertility

Because of the potential for serious adverse reactions in breastfed infants from TECENTRIQ, advise female patients not to breastfeed while taking TECENTRIQ and for at least 5 months after the last dose
Based on animal studies, TECENTRIQ may impair fertility in females of reproductive potential while receiving treatment

Most Common Adverse Reactions
The most common adverse reactions (rate ≥20%) in patients who received TECENTRIQ in combination with cobimetinib and vemurafenib for melanoma were rash (75%), musculoskeletal pain (62%), fatigue (51%), hepatotoxicity (50%), pyrexia (49%), nausea (30%), pruritus (26%), edema (26%), stomatitis (23%), hypothyroidism (22%), and photosensitivity reaction (21%).

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Prescribing Information for additional Important Safety Information.